CCF: Cleveland Clinic Foundation; ECOG PS: Eastern Cooperative Oncology Group Performance Score; IKCWG: International Kidney Cancer Working Group; MSKCC: Memorial Sloan–Kettering Cancer Center.
2013;13(6):697-709. In the pivotal Phase III trial of pazopanib, PFS was significantly prolonged by pazopanib treatment compared with placebo, regardless of MSKCC risk category. However ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback